Copyright
©The Author(s) 2016.
World J Gastroenterol. Jun 21, 2016; 22(23): 5400-5405
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5400
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5400
Table 2 Detailed description of patients at therapy start
| Patient | Age | Gender | Primary | UICC | Liver metastases | Lunge metastases | Number of pre-therapies |
| 1 | 68 | M | Sigma | IV | 1 | 1 | 3 |
| 2 | 52 | M | Colon desc. | IV | 0 | 1 | 3 |
| 3 | 51 | M | Sigma | IV | 1 | 1 | 3 |
| 4 | 81 | M | Rectum | IV | 1 | 1 | 3 |
| 5 | 59 | F | Colon desc. | IV | 1 | 1 | 3 |
| 6 | 74 | M | Sigma | IV | 0 | 1 | 3 |
| 7 | 74 | M | Rectum | IV | 1 | 0 | 4 |
| 8 | 65 | F | Sigma | IV | 1 | 1 | 6 |
| 9 | 69 | M | Sigma | IV | 0 | 1 | 3 |
| 10 | 61 | M | Colon desc. | IV | 0 | 0 | 4 |
- Citation: Martchenko K, Schmidtmann I, Thomaidis T, Thole V, Galle PR, Becker M, Möhler M, Wehler TC, Schimanski CC. Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World J Gastroenterol 2016; 22(23): 5400-5405
- URL: https://www.wjgnet.com/1007-9327/full/v22/i23/5400.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i23.5400